Table 3.
Main characteristics of the participants included in the systematic review.
| Studies | Number of Participants/EG:CG | Age (SD) | Male:Female | Time After Stroke (SD) | Ischemic:Hemorrhagic |
|---|---|---|---|---|---|
| Akbari et al. (2006) [33] | N:34 17:17 |
EG 49.3 (7.1) years | EG 10:7 | EG 34.5 (26.37) months | EG ND |
| CG 48.8 (3) years | CG 9:8 | CG 35.3 (27.5) months | CG ND | ||
| Coroian et al. (2018) [29] | N: 20 10:10 |
EG 63.6 (12.6) years | EG 8:2 | EG 32.2 (12.8–629.6) months | EG 9:1 |
| CG 63.6 (10.6) years | CG 8:2 | CG 29.1 (7.6–90.1) months | CG 7:3 | ||
| Dehno et al. (2021) [30] | N: 26 13:13 |
EG 53 (9.36) years | EG 7:6 | EG 95.22 (37.14) days | EG 11:2 |
| CG 49.77 (15.48) years | CG 6:7 | CG 101.62 (32.39) days | CG 12:1 | ||
| Fernandes et al. (2015) [32] | N: 16 9:7 |
EG 58 (6) years | EG 9:0 | EG 15 (5) days | EG 6:3 |
| CG 58 (7) years | CG 7:0 | CG 17 (4) days | CG 5:2 | ||
| Fernandez et al. (2016) [34] | N: 29 14:15 |
EG 61.2 (9.8) years | EG 11:3 | EG 3.5 (3.6) years | EG 9:5 |
| CG 65.7 (12.7) years | CG 11:4 | CG 4.3 (4.9) years | CG 11:4 | ||
| Flansbjer et al. (2008) [35] | N: 24 15:9 |
EG 61 (5) years | EG 9:6 | EG 18.9 (7.9) months | EG 12:3 |
| CG 60 (5) years | CG 5:4 | CG 20.0 (11.6) months | CG 6:3 | ||
| Mun et al. (2019) [36] | N:20 10:10 |
EG 53.1 (13.4) years | EG 8:2 | EG 20.3 (14.4) months | EG 3:7 |
| CG 54.0 (9.1) years | CG 8:2 | CG 15.8 (10.2) months | CG 7:3 | ||
| Lattouf et al. (2021) [37] | N: 37 19:18 |
EG 65.1 (11.7) years | EG 11:8 | EG 11.61 (4.07) months | EG 14:5 |
| CG 68.7 (12.4) years | CG 11:7 | CG 12.26 (5.41) months | CG 14:4 | ||
| Patten et al. (2013) [31] | N: 19 9:10 |
GA 64.7 (9.7) years | GA 6:3 | GA 14.7 (2.7) months | GA 7:2 |
| GB 72.9 (11.1) years | GB 9:1 | GB 11.4 (4.3) months | GB 7:3 |
CG, Control group; EG, Experimental group; GA, Group A; GB, Group B; ND, Not described.